A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis
批准号:
10063724
负责人:
VICTORIA P WERTH
金额:
$42.77万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2024-06-30
关键词:
Afferent NeuronsAftercareAgonistAnti Inflammatory AnalgesicsAreaAutoimmune DiseasesBiopsyCD4 Positive T LymphocytesCNR2 geneCancer EtiologyCannabinoidsCellsClinicalClinical ResearchCutaneousCytokine SignalingCytometryDataDendritic CellsDermalDermatomyositisDevelopmentDiseaseDouble-Blind MethodDown-RegulationFlow CytometryFundingGene ExpressionGenetic TranscriptionGoalsIL4 geneIRF3 geneIn VitroInflammationInflammatoryInnate Immune ResponseInterferon Type IIInterferon-alphaInterferon-betaInterferonsInterleukinsInternationalLabelLeadLesionLightLupusMalignant NeoplasmsMeasuresMessenger RNAMolecularMusMyelogenousNervePathogenesisPathway interactionsPatient-Focused OutcomesPatientsPeripheral Blood Mononuclear CellPhasePlacebosProductionPruritusQuality of lifeRandomizedRandomized Controlled TrialsRefractoryRegulationReportingResolutionRiskRoleSamplingScientific Advances and AccomplishmentsSignal TransductionSkinStainsT-Cell ActivationT-LymphocyteT-Lymphocyte SubsetsTh1 CellsTherapeuticTimeTissuesUnited States National Institutes of HealthWorkarmcell typecytokineeffective therapyin vivoknock-downlaser capture microdissectionnovelnovel therapeutic interventionnovel therapeuticsperipheral bloodpersonalized therapeuticphase II trialphase III trialplacebo groupprimary outcomeprogramsreceptorresponsesafety studysecondary outcomeskin disorderskin lesiontranscription factortreatment duration
中文摘要
摘要
皮肌炎(DM)是一种引起显著皮肤活动的多器官自身免疫性疾病。
和严重瘙痒,这两者都恶化了患者的生活质量(QOL)。尽管它在临床上
然而,重要的是,糖尿病患者皮肤活动和瘙痒的发病机制仍不清楚。
明白了。因此,在过去的70年里,没有任何治疗糖尿病的新疗法被批准。
目前可用的非标签疗法往往无效或有重大风险。我们
最近成功完成了一项由美国国立卫生研究院资助的利纳巴松第二阶段随机对照试验,
一种新的非精神活性CB2反向激动剂,用于治疗皮肤型糖尿病。Lenabasum
在皮肤病活跃度、瘙痒和关键的QOL指标方面有显著改善。
在我们实验室使用有限数量的皮损皮肤活检进行的机制研究
从试验中证明,来纳香降低皮肤CD4T细胞的数量和
干扰素、干扰素γ和白介素31的真皮染色区域。这四个都不是
安慰剂组的参数发生了变化。这些变化中的前三个显著
与皮肤病活动性的改善有关。干扰素γ皮肤染色的减少
IL31和IL31均与瘙痒改善显著相关。我们最近的工作证明
糖尿病患者皮肤中显著的髓系树突状细胞(MDCs),与
许多狼疮患者皮肤中浆细胞样树突状细胞和干扰素α的优势
病人。考虑到之前报道的糖尿病患者皮肤中显著的干扰素信号,以及
干扰素和皮肤病活性对来纳假单胞菌的反应,我们现在建议评估其作用
在DM的干扰素的生产中的MDCS。我们有机会扩大科学研究领域
我们在即将到来的Lenabasum国际试验的第二阶段试验中取得的进展
对于DM。我们假设,莱纳巴松通过MDCS上的CB2受体发挥作用,减少
干扰素通过对IRF-3、-5和-7的影响表达MDC。我们还假设
Lenabasum,通过下调MDCS的干扰素或直接作用于T细胞
细胞,减少干扰素γ和白介素31在皮肤中的产生。利纳巴松对糖尿病患者的治疗作用
在3期试验中,我们将确定与皮肤相关的细胞和分子通路的变化
疾病活动性和瘙痒可预测或与临床改善相关。我们还将
糖尿病患者活动和瘙痒促进途径及其改善的机制研究
加了羊肚菌。我们利用即将到来的第三阶段试验的样本进行的拟议研究将
加深我们对莱纳巴斯菌工作原理的了解,从而揭示关键疾病
这可能会为更多新的治疗方法提供基础。
英文摘要
Abstract
Dermatomyositis (DM) is a multiorgan autoimmune disease that causes significant skin activity
and severe pruritus, both of which worsen the patients’ quality of life (QoL). Despite its clinical
importance, however, the pathogenesis of skin activity and itch in DM remains poorly
understood. Accordingly, no new therapies for DM have been approved in the last 70 years.
Currently available off-label therapies are frequently ineffective or have significant risks. We
recently completed a successful NIH-funded phase 2 randomized controlled trial of lenabasum,
a novel nonpsychoactive CB2 inverse agonist, to treat skin-predominant DM. Lenabasum
produced significant improvements in skin disease activity, itch, and key QoL measures.
Mechanistic studies performed in our lab using the limited number of biopsies of lesional skin
from the trial demonstrated that lenabasum decreased the numbers of dermal CD4+ T-cells and
dermal staining areas for interferon (IFN)ß, IFNγ, and interleukin (IL)31. None of these four
parameters changed in the placebo group. The first three of these changes significantly
correlated with improvement in skin disease activity. The decreases in dermal staining for IFNγ
and IL31 each significantly correlated with improvement in itch. Our recent work demonstrates
prominent myeloid dendritic cells (mDCs) in the skin of patients with DM, in contrast to the
predominance of plasmacytoid DCs (pDCs) and the IFNα signature in the skin of many lupus
patients. Given the prominent IFNß signal in skin previously reported in DM and the decrease in
IFNß and skin disease activity in response to lenabasum, we now propose to evaluate the role
of mDCs in the production of IFNß in DM. We have an opportunity to expand the scientific
advances we made in the phase 2 trial in an upcoming phase 3 international trial of lenabasum
for DM. We hypothesize that lenabasum, acting through the CB2 receptor on mDCs, decreases
mDC expression of IFNß through effects on IRF-3, -5, and -7. We also hypothesize that
lenabasum, either through the downregulation of IFNß from mDCs or by direct effects on T
cells, decreases production of IFNγ and IL31 in skin. In DM patients treated with lenabasum in
the phase 3 trial, we will identify cellular and molecular changes in pathways relevant to skin
disease activity and itch that predict or correlate with clinical improvements. We will also
perform mechanistic studies of pathways promoting activity and itch in DM and the improvement
with lenabasum. Our proposed studies utilizing samples from the upcoming phase 3 trial will
enhance our understanding of how lenabasum works, thereby shedding light on key disease
mechanisms and possibly providing a basis for additional novel therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis
-
批准号:10186633
-
项目类别:
-
资助金额:$40.71万
-
财政年份:2020
-
负责人:VICTORIA P WERTH
-
依托单位:
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis
-
批准号:10600343
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2020
-
负责人:VICTORIA P WERTH
-
依托单位:
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis
-
批准号:10437840
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2020
-
负责人:VICTORIA P WERTH
-
依托单位:
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis
-
批准号:10656390
-
项目类别:
-
资助金额:$40.24万
-
财政年份:2020
-
负责人:VICTORIA P WERTH
-
依托单位:
Request for a CyTOF Helios System
-
批准号:9211981
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:VICTORIA P WERTH
-
依托单位:
Treatment of Dermatomyositis with Ajulemic Acid, a Non-Psychoactive Cannabinoid
-
批准号:8691537
-
项目类别:
-
资助金额:$17.6万
-
财政年份:2014
-
负责人:VICTORIA P WERTH
-
依托单位:
The role of TNF-Alpha in cutaneous integrity
-
批准号:8659185
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:VICTORIA P WERTH
-
依托单位:
The role of TNF-Alpha in cutaneous integrity
-
批准号:8803242
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:VICTORIA P WERTH
-
依托单位:
The role of TNF-Alpha in cutaneous integrity
-
批准号:8441176
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:VICTORIA P WERTH
-
依托单位:
ASSESS THE SAFETY OF PI-0824 IN PATIENTS WITH PEMPHIGUS VULGARIS
-
批准号:7199119
-
项目类别:
-
资助金额:$0.14万
-
财政年份:2004
-
负责人:VICTORIA P WERTH
-
依托单位:
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE
-
批准号:6771844
-
项目类别:
-
资助金额:$10.6万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
Patient-oriented research in skin autoimmune disease
-
批准号:8228173
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE
-
批准号:6632554
-
项目类别:
-
资助金额:$10.29万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
Patient-oriented research in skin autoimmune disease
-
批准号:7582417
-
项目类别:
-
资助金额:$14.78万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE
-
批准号:6915564
-
项目类别:
-
资助金额:$10.92万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
Patient-oriented research in skin autoimmune disease
-
批准号:7385523
-
项目类别:
-
资助金额:$14.5万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE
-
批准号:6511747
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
PATIENT-ORIENTED RESEARCH IN SKIN AUTOMMUNE DISEASE
-
批准号:6226996
-
项目类别:
-
资助金额:$9.7万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
Patient-oriented research in skin autoimmune disease
-
批准号:8033765
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2001
-
负责人:VICTORIA P WERTH
-
依托单位:
海外基金